Tests atorvastatin to reduce hearing loss from cisplatin in head and neck cancer
Tests atorvastatin, or a placebo, for hearing loss in adults with head and neck cancer.
Key facts
- Who runs it
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Where
- Atlanta, Baltimore, Bethesda, Fairfax, and Rochester, United StatesSee the 5 sites
- Trial code
- Registry title
- Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 224 people, planned
- Started
- 10 Jul 2024
- Expected to end
- 31 Aug 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Placebo
- Atorvastatin
- Record updated
- 2 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with squamous cell carcinoma of the head and neck who will get cisplatin-based chemotherapy with radiation. It tests whether atorvastatin lowers hearing loss caused by cisplatin.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Squamous cell carcinoma of the head and neck, confirmed by a pathology review. Planned treatment is cisplatin-based chemotherapy with radiation meant to remove all of the disease, or chemotherapy given before other treatment. Planned radiation dose to the cochlea is under 35 Gy.
- Earlier treatment
- People cannot have had cisplatin chemotherapy before. People who take a statin drug now cannot join the study drug part.
- Biomarker or test result
- Hearing at or better than 70 dB HL at 1, 2 and 4 kHz in at least one ear. Liver, kidney and muscle enzyme blood values under 1.5 times the upper limit of normal.
Main reasons for not taking part
- Currently taking a statin drug
- Flat Type B tympanogram in both ears, or cochlear implants in both ears
- Liver or kidney disease that would interfere with taking atorvastatin 40 mg daily
- Pregnancy, breastfeeding, or plan to become pregnant
- Current use of certain drugs, such as cimetidine, ketoconazole, cyclosporine or protease inhibitors, or expected use of aminoglycoside antibiotics
The registry criteria, word for word
Show all 22 criteriaShow less
Who cannot take part
- Subjects currently taking a statin drug
- Subjects with bilateral cochlear implants
- Subjects with a history of prior treatment with cisplatin chemotherapy
- Current use of cimetidine, spironolactone, ketoconazole, cyclosporine, protease inhibitors, gemfibrozil, clarithromycin or itraconazole
- Expected concomitant use of aminoglycoside antibiotics
- Pre-existing liver or kidney disease that in the opinion of the investigator would interfere with taking Atorvastatin 40 mg daily
- Known allergic reactions to components of atorvastatin or the placebo
- Other severe or unstable medical conditions which clinical site PI believes increase risk to safety or ability to complete study
- Children will be excluded because HNSCC in children under age 18 is exceedingly rare
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Subjects with bilateral flat, Type B tympanogram
- Staff members of the NIDCD Sections and of the lead site investigators headed by the PIs
- Pregnancy, lactation, or plan to become pregnant
Other criteria
- INCLUSION CRITERIA:; In order to be eligible to participate in this study, an individual must meet all of the following criteria evaluated by the study team, including an on-site oncologist:
- Willingness and ability to comply with and participate in all study procedures and availability for the duration of the study
- Ability to provide consent and provision of signed and dated informed consent form
- Adult subjects, aged >=18
- Diagnosed with squamous cell carcinoma of the head and neck, confirmed by a pathologic review of surgical or biopsy specimen(s), who meet standard clinical and laboratory criteria and will undergo treatment with concomitant cisplatin-based chemotherapy and radiation with curative intent or treatment with neoadjuvant chemotherapy (NAC). This includes subjects who will be treated with either intensity-modulated radiation therapy (IMRT) or proton radiotherapy, with planned dose to the cochlea <35 Gy (to limit confounding effects of radiation64-67). Patients receiving immunotherapy in addition to cisplatin chemoradiation are eligible. Subjects treated with either high-dose cisplatin (typically 100 mg/m\^2 x 2-3 doses every three weeks) or low-dose, weekly cisplatin (typically 40 mg/m\^2 x 6-7 doses weekly) may enroll. Cisplatin in the neo-adjuvant setting may be given within a combination chemotherapy regimen (e.g TPF= Docetaxel, Cisplatin and 5FU or DC = Docetaxel Cisplatin)
- Subjects must have hearing thresholds at or better than 70 dB HL at 1, 2, and 4 kHz in at least one ear at the time of their baseline audiogram. CTCAE criteria (primary endpoint) and ASHA criteria (secondary endpoint) are based on changes in hearing in at; least one ear with one ototoxicity event/grade assigned per person
- Baseline laboratory tests with lab values <1.5x the upper limit of normal: aspartate aminotransferase (AST or SGOT); alanine aminotransferase; creatine phosphokinase, creatinine
- Ability to take oral medication by mouth or by feeding tube and willingness to adhere to the daily atorvastatin or placebo regimen
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to enrollment and agreement to use such a method during study participation and for an additional 8 weeks after the end of atorvastatin administration
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in United States
- Winship Cancer Institute at Emory UniversityAtlanta, United StatesContact: Nicole SchmittTaking people
- University of Maryland Medical CenterBaltimore, United StatesContact: Adam KaufmanTaking people
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Katharine A Fernandez, Au.D.Taking people
- Inova Schar Cancer CenterFairfax, United StatesContact: John Deeken, M.D.Taking people
- Wilmot Cancer Institute at the University of Rochester Medical Center in New YorRochester, United StatesContact: Shawn NewlandsTaking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss.
Objective:
To find out if atorvastatin reduces hearing loss in people treated with cisplatin and radiation.
Eligibility:
People ages 18 and older with squamous cell carcinoma of the head and neck who will undergo treatment with cisplatin-based chemotherapy and radiation
Design:
Participants will be screened with their medical records.
Participants currently taking a cholesterol-lowering statin medication are invited to participate in the observational arm of the study. Those not taking such a medication are invited to participate in the interventional arm of the study.
All participants will have 3 study visits for the purpose of evaluating hearing. One before starting cisplatin treatment, one within 3 months of completing cancer treatment, and one within 2 years of completing cancer treatment. They will have tympanograms. A small flexible tip will be placed in the ear canal. A puff of air will be delivered to assess mobility of the ear drum. They will have hearing tests. They will wear headphones. They will listen to tones that vary in loudness. They will be asked to indicate when they hear a sound. They will complete 3 questionnaires at the time of each hearing test.
Participants will have 2 visits for blood tests. These will occur upon consent and 12 weeks after. They will be randomly assigned to take the study drug or placebo orally, once daily. They will take it during cisplatin treatment and for 3 months after treatment.
Long-term follow up will include a chart review 2 years after participants complete their cisplatin therapy.
The 2 groups in the trial
- 1Treatment being tested
Atorvasatatin (40 mg)
Treatment: Atorvastatin
- 2Placebo, for comparison
Placebo
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase II Interventional Study Using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- Plain-language title
- Tests atorvastatin to reduce hearing loss from cisplatin in head and neck cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04915183, who can take part
- Record updated
- 2 September 2026